BACK

Kelly Curtin

Kelly Curtin

Managing Director

London Office  |  kelly.curtin@torreya.com   |   +44 (0) 207 451 4564

Kelly Curtin, a Managing Director on Torreya’s European team, advises clients on strategic transactions across the life sciences industry. She has 20 years of experience in investment banking, primarily in the healthcare industry.

Her experience includes strategic transactions across a wide spectrum of the life sciences, including biotechnology, pharma, specialty pharma, generics, healthcare services and medical devices. Kelly has led cross-border M&A, carve-outs, licensing transactions and divestments as well as executed a range of equity and debt financings.

Recent transactions on which Kelly has worked at Torreya include the acquisition of Dara Biosciences by Midatech plc, the licensing of European rights for Shield’s Feraccru to Norgine and the sale of MTPUS to Kanwa Holdings, an affiliate of Barings.

Before joining Torreya in 2014, Kelly was a Director in Credit Suisse’s Mergers & Acquisitions group in Chicago and London.

Kelly holds a B.A. in Law, Jurisprudence and Social Thought from Amherst College.

Selected Transactions

Mereo Biopharma
License of
Navicixizumab to
Oncologie
Up to $306 million
January 2020
Midatech Pharma PLC
Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC
None
Up to $19 million
November 2018
Lysogene
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
Shield Therapeutics
Licensing agreement for Feraccru® in Europe, Australia and New Zealand with
Norgine
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015